Strategic Initiative

Slingshot members are tracking this corporate initiative:

AbbVie buys Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details - Rovalpituzumab tesirine (Rova-T) is a biomarker-specific antibody drug conjugate targeting cancer stem cell protein DLL3
- Compelling data on Rova-T was presented at the European Society of Medical Oncology demonstrating overall response rates of 44 percent in DLL-expressing small cell lung cancer (SCLC) patients who have previously failed one or more standard therapies
- Rova-T represents a multi-billion dollar peak revenue opportunity with expected commercialization in 2018
- Long-term data on Rova-T, including overall survival, will be presented at the 2016 ASCO Annual Meeting; Rova-T was recently selected to be included in the Best of ASCO Program
- Expands AbbVie's oncology pipeline with four additional early-stage clinical compounds in solid tumor indications and a significant portfolio of pre-clinical assets
- Transaction valued at approximately $5.8 billion, with additional milestones payable upon successful completion of pre-determined clinical and regulatory achievements
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Apr 28, 2016
Projected Implementation:
Q2, 2016
Relevance Tracked Until:
Q4, 2016
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Rova-t, Small Cell Lung Cancer, Tumor, Registrational Trials, Stem Cells, Delta-like Protein 3, Dll3, Sclc, Antibody-drug Conjugate